Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 18, 2008Diabetes Obesity and Metabolism

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does vildagliptin improve HbA1c in patients with T2DM inadequately controlled with a sulphonylurea?

Population

515 patients with type 2 diabetes mellitus inadequately controlled with prior sulphonylurea monotherapy.

Comparison

Vildagliptin 50 mg once or twice daily added to… vs Placebo added to glimepiride 4 mg once daily

Design

RCT, randomized, double-blind

Follow-up

24 weeks

Authors

AGA. J. GarberHouston MethodistJFJames E. FoleyHarvard UniversityMBMary Ann BanerjiState University of New York

Discussion

Loading...

Member takes

Overview

Supports vildagliptin add-on to sulfonylurea in T2DM; confirms benefit in this combination from RCT data.

Structured PICO

Does vildagliptin improve HbA1c in patients with T2DM inadequately controlled with a sulphonylurea?

P
Population
515 patients with type 2 diabetes mellitus (T2DM) inadequately controlled (HbA1c 7.5 to 11%) with prior sulphonylurea (SU) monotherapy.
I
Intervention
Vildagliptin 50 mg once or twice daily added to glimepiride 4 mg once daily for 24 weeks
C
Comparator
Placebo added to glimepiride 4 mg once daily
O
Outcome
Adjusted mean changes from baseline to end-point in HbA1c at 24 weekssurrogate

The addition of vildagliptin to glimepiride significantly improves glycemic control in patients with T2DM inadequately controlled on sulfonylurea monotherapy, with a low risk of hypoglycemia.

Cite This Study

Garber et al. (2008) studied this question.

synapsesocial.com/papers/6a786b77d8eb58afc2be871chttps://doi.org/10.1111/j.1463-1326.2008.00859.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin2007 · 526 citations
  2. 2Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes2004 · 488 citations
  3. 3Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance1992 · 813 citations
  4. 4Oral Antihyperglycemic Therapy for Type 2 Diabetes2002 · 1,069 citations
  5. 5Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus Progressive Requirement for Multiple Therapies (UKPDS 49)1999 · 2,391 citations